Related references
Note: Only part of the references are listed.The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review
A. F. de Groot et al.
CANCER TREATMENT REVIEWS (2018)
Denosumab: A Review in Postmenopausal Osteoporosis
Emma D. Deeks
DRUGS & AGING (2018)
RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-κB activation and EGFR signaling
Chaido Sirinian et al.
ONCOGENE (2018)
RANKL and RANK: From Mammalian Physiology to Cancer Treatment
Shuan Rao et al.
TRENDS IN CELL BIOLOGY (2018)
Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.
Michael Gnant et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.
Robert E. Coleman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort
Danja Sarink et al.
BMC CANCER (2018)
Identification of novel human RANK isoforms generated through alternative splicing. Implications in breast cancer cell survival and migration (vol 14, R112, 2012)
Anastasios D. Papanastasiou et al.
BREAST CANCER RESEARCH (2018)
Incidence and Mortality and Epidemiology of Breast Cancer in the World
Mahshid Ghoncheh et al.
Asian Pacific Journal of Cancer Prevention (2017)
Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials
Andrew S. Gdowski et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
RANK and EGFR in invasive breast carcinoma
Anastasios D. Papanastasiou et al.
CANCER GENETICS (2017)
Distribution of RANK and RANK Ligand in Normal Human Tissues as Determined by an Optimized Immunohistochemical Method
Clive R. Taylor et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2017)
Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression
Monica E. Reyes et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
Peyman Hadji et al.
JOURNAL OF BONE ONCOLOGY (2017)
RANKL/RANK control Brca1 mutation-driven mammary tumors
Verena Sigl et al.
CELL RESEARCH (2016)
Role of the RANK/RANKL pathway in breast cancer
Ludwig Kiesel et al.
MATURITAS (2016)
RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers
Emma Nolan et al.
NATURE MEDICINE (2016)
Osteoprotegerin rich tumor microenvironment: implications in breast cancer
Sudeshna Goswami et al.
ONCOTARGET (2016)
RANKL/RANK: from bone loss to the prevention of breast cancer
Verena Sigl et al.
OPEN BIOLOGY (2016)
Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis
Sudeshna Goswami et al.
BMC CANCER (2015)
SEOM clinical guidelines in metastatic breast cancer 2015
J. Gavila et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2015)
OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone
Penelope D. Ottewell et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Michael Gnant et al.
LANCET (2015)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
R. Coleman et al.
LANCET (2015)
Osteoprotegerin in breast cancer: beyond bone remodeling
Michael Weichhaus et al.
MOLECULAR CANCER (2015)
Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression
Xin Ye et al.
TRENDS IN CELL BIOLOGY (2015)
RANK Signaling Amplifies WNT-Responsive Mammary Progenitors through R-SPONDINI
Purna A. Joshi et al.
STEM CELL REPORTS (2015)
RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy
Hatem A. Azim et al.
BREAST CANCER RESEARCH (2015)
Bone health in cancer patients: ESMO Clinical Practice Guidelines
R. Coleman et al.
ANNALS OF ONCOLOGY (2014)
RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase
Hong Hu et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
RANKL/RANK - From bone physiology to breast cancer
Verena Sigl et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2014)
Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer
Irene Zinonos et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Expression of Receptor Activator of Nuclear Factor Kappa-B as a Poor Prognostic Marker in Breast Cancer
Hyung Seok Park et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
NF-κB Activation-Induced Anti-apoptosis Renders HER2-Positive Cells Drug Resistant and Accelerates Tumor Growth
Shannon T. Bailey et al.
MOLECULAR CANCER RESEARCH (2014)
Osteoprotegerin expression in triple-negative breast cancer cells promotes metastasis
Michael Weichhaus et al.
CANCER MEDICINE (2014)
Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond
Matthew C. Walsh et al.
FRONTIERS IN IMMUNOLOGY (2014)
A NIK-IKKα Module Expands ErbB2-Induced Tumor-Initiating Cells by Stimulating Nuclear Export of p27/Kip1
Weizhou Zhang et al.
CANCER CELL (2013)
Targeting RANKL in breast cancer: bone metastasis and beyond
Hamdy Azim et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2013)
Alternative splicing generates a truncated isoform of human TNFRSF11A (RANK) with an altered capacity to activate NF-κB
Chaido Sirinian et al.
GENE (2013)
Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines
Masanobu Tsubaki et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2013)
The sex hormone system in carriers of BRCA1/2 mutations: a case-control study
Martin Widschwendter et al.
LANCET ONCOLOGY (2013)
Lessons Learned From the Women's Health Initiative Trials of Menopausal Hormone Therapy
Jacques E. Rossouw et al.
OBSTETRICS AND GYNECOLOGY (2013)
Progesterone/RANKL Is a Major Regulatory Axis in the Human Breast
Tamara Tanos et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
A New Achilles Heel in Breast Cancer?
George Sflomos et al.
ONCOTARGET (2013)
Progestin effects on cell proliferation pathways in the postmenopausal mammary gland
Charles E. Wood et al.
BREAST CANCER RESEARCH (2013)
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors
Yun-Ju Chen et al.
BREAST CANCER RESEARCH (2013)
RANK Induces Epithelial-Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
Marta Palafox et al.
CANCER RESEARCH (2012)
Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis
William C. Dougall
CLINICAL CANCER RESEARCH (2012)
RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis
J. T. Ney et al.
GEBURTSHILFE UND FRAUENHEILKUNDE (2012)
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab
David L. Lacey et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
RANKL Employs Distinct Binding Modes to Engage RANK and the Osteoprotegerin Decoy Receptor
Christopher A. Nelson et al.
STRUCTURE (2012)
Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration
Anastasios D. Papanastasiou et al.
BREAST CANCER RESEARCH (2012)
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Rohini Roy et al.
NATURE REVIEWS CANCER (2012)
Bone metastasis in breast cancer: The story of RANK-Ligand
Hamdy A. Azim et al.
JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE (2012)
Anticancer Efficacy of Apo2L/TRAIL Is Retained in the Presence of High and Biologically Active Concentrations of Osteoprotegerin In Vivo
Irene Zinonos et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Expression Pattern of Receptor Activator of NFκB (RANK) in a Series of Primary Solid Tumors and Related Bone Metastases
Daniele Santini et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2011)
RANKL/RANK-beyond bones
Reiko Hanada et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2011)
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling
Wei Tan et al.
NATURE (2011)
Receptor Activator of NF-κB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients
Daniele Santini et al.
PLOS ONE (2011)
RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis
Daniel Schramek et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2011)
Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis
Jude Canon et al.
BONE (2010)
Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer
J. J. Cody et al.
CANCER GENE THERAPY (2010)
TGF-β Pathway as a Therapeutic Target in Bone Metastases
Patricia Juarez et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor expression
Atish Mukherjee et al.
FASEB JOURNAL (2010)
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison T. Stopeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis
Eva Gonzalez-Suarez et al.
NATURE (2010)
Control of mammary stem cell function by steroid hormone signalling
Marie-Liesse Asselin-Labat et al.
NATURE (2010)
Progesterone induces adult mammary stem cell expansion
Purna A. Joshi et al.
NATURE (2010)
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer
Daniel Schramek et al.
NATURE (2010)
Her2 activates NF-κB and induces invasion through the canonical pathway involving IKKα
E. C. Merkhofer et al.
ONCOGENE (2010)
Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland
Manfred Beleut et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The CD10 Enzyme Is a Key Player to Identify and Regulate Human Mammary Stem Cells
Elodie Bachelard-Cascales et al.
STEM CELLS (2010)
Nuclear Factor-κB Enhances ErbB2-Induced Mammary Tumorigenesis and Neoangiogenesis in Vivo
Manran Liu et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse
Rodrigo Fernandez-Valdivia et al.
DEVELOPMENTAL BIOLOGY (2009)
Osteoprotegerin Production by Breast Cancer Cells Is Suppressed by Dexamethasone and Confers Resistance Against TRAIL-induced Apoptosis
Tilman D. Rachner et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
The basics of epithelial-mesenchymal transition
Raghu Kalluri et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Negative Prognostic Impact of the Coexpression of Epidermal Growth Factor Receptor and c-erbB-2 in Locally Advanced Cervical Cancer
Jose Perez-Regadera et al.
ONCOLOGY (2009)
RANK/RANKL: Regulators of Immune Responses and Bone Physiology
Andreas Leibbrandt et al.
YEAR IN IMMUNOLOGY 2008 (2008)
Functions of RANKL/RANK/OPG in bone modeling and remodeling
Brendan F. Boyce et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2008)
17β-Estradiol inhibits osteoprotegerin production by the estrogen receptor-α-positive human breast cancer cell line MCF-7
Tilman D. Rachner et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Progestin-regulated luminal cell and myoepithelial cell-specific responses in mammary organoid culture
Sandra Z. Haslam et al.
ENDOCRINOLOGY (2008)
The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance
Taishin Akiyama et al.
IMMUNITY (2008)
Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling
Tacghee Yi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2008)
Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis
Diptiman Chanda et al.
MOLECULAR THERAPY (2008)
Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis
Jude R. Canon et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
Investigating the interaction between osteoprotegerin and receptor activator of NF-κB or tumor necrosis factor-related apoptosis-inducing ligand
Srdjan Vitovski et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini
Eva Gonzalez-Suarez et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Biology of RANK, RANKL, and osteoprotegerin
Brendan F. Boyce et al.
ARTHRITIS RESEARCH & THERAPY (2007)
Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist
Aleksandra Jovanovic Poole et al.
SCIENCE (2006)
The RANK/RANKL/OPG triad in cancer-induced bone diseases
William C. Dougall et al.
CANCER AND METASTASIS REVIEWS (2006)
Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data
P. van der Groep et al.
JOURNAL OF CLINICAL PATHOLOGY (2006)
Osteoprotegerin (OPG) - a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?
SS Cross et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Regulation of cancer cell migration and bone metastasis by RANKL
DH Jones et al.
NATURE (2006)
Receptor activator of NF-κB ligand regulates the proliferation of mammary epithelial cells via Id2
NS Kim et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Generation of a functional mammary gland from a single stem cell
M Shackleton et al.
NATURE (2006)
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappa B ligand (RANKL) in human breast tumours
C Van Poznak et al.
JOURNAL OF CLINICAL PATHOLOGY (2006)
The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells
YX Ma et al.
MOLECULAR ENDOCRINOLOGY (2006)
Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo -: a role in tumour cell survival?
I Holen et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation
S Diermeier et al.
EXPERIMENTAL CELL RESEARCH (2005)
Role of progestins in contraception
R Erkkola et al.
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA (2005)
NF-KB activation in human breast cancer specimens and its role in cell proliferation and apoptosis
DK Biswas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer
M Razandi et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Osteoprotegerin in human milk: A potential role in the regulation of bone metabolism and immune development
K Vidal et al.
PEDIATRIC RESEARCH (2004)
Receptor activator of NF-κB ligand induction via Jak2 and Stat5a in mammary epithelial cells
S Srivastava et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform
B Mulac-Jericevic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Breast cancer and hormone-replacement therapy in the Million Women Study
E Banks et al.
LANCET (2003)
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
A Almasan et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2003)
Osteoclast differentiation and activation
WJ Boyle et al.
NATURE (2003)
The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts
S Bord et al.
BONE (2003)
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases
JJ Body et al.
CANCER (2003)
Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial
JE Rossouw et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
ND Kauff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Cancer susceptibility and the functions of BRCA1 and BRCA2
AR Venkitaraman
CELL (2002)
The importance of being a myoepithelial cell
MA Deugnier et al.
BREAST CANCER RESEARCH (2002)
IKKα provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development
YX Cao et al.
CELL (2001)
Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice
KU Wagner et al.
TRANSGENIC RESEARCH (2001)
BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor
L Zheng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
RE Coleman
CANCER TREATMENT REVIEWS (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3
XM Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development
JE Fata et al.
CELL (2000)
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo
DL Lacey et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
